SPETTY, thanks for the reinforcing the thoughts on some of my previous posts.
My feelings exactly.
Positive company dynamics going forward, which we all are hoping for (including the big pharmas and instituions waiting on the sidelines to enter, imo) and possible r/s timing, are the key, imo.
I'm not sure how to 'read' the fact that Rabin is still in his acting capacity.
One thought is the board is assessing the merits of a new management relationship with a new partner, or the board is pleased with Rabin, will assess phase I/II and take steps to continue going it alone?
Once phase I/Ii start to become apparent, that will be the trigger event, imo, that will define the next significant steps for the board and company.
News 
Market Data 
Discover 
AI
